Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jasper Therapeutics (JSPR)
NASDAQ:JSPR
Holding JSPR?
Track your performance easily
JSPR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.00 - $31.01
Previous Close$22.69
Volume270.48K
Average Volume (3M)261.23K
Market Cap
$342.74M
Enterprise Value$252.31M
Total Cash (Recent Filing)$92.50M
Total Debt (Recent Filing)$2.07M
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Mar 11, 2025EPS Estimate
-$1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.10
Shares Outstanding15,001,353
10 Day Avg. Volume268,128
30 Day Avg. Volume261,226
Standard Deviation0.40
R-Squared0.09
Alpha-0.00680
Financial Highlights & Ratios
Price to Book (P/B)3.69
Price to Sales (P/S)19.04
Price to Cash Flow (P/CF)-7.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit28.03
Enterprise Value/Ebitda-3.75
Forecast
1Y Price Target
$71.00Price Target Upside189.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Jasper Therapeutics News
PremiumCompany Announcements
Jasper Therapeutics Advances in Antibody Therapy Development
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPositive data from the SPOTLIGHT study increase confidence in positive BEACON data, with a demonstrated dose response in efficacy and no safety concerns.
Market OpportunityThere is a meaningful opportunity with Jasper's briquilimab for patients not well controlled with antihistamines, targeting a significant number of patients in the US suffering from chronic urticaria.
Strategic DevelopmentsAnalyst is optimistic on Jasper's strategy to develop briquilimab for chronic spontaneous urticaria and chronic inducible urticaria with multiple studies underway.
Bears Say
Adverse EffectsDiscontinuation rates increased significantly (25%) with 8%-13% being driven by on-target adverse effects.
Drug DiscontinuationDevelopment in LR-MDS has been discontinued.
Safety ConcernsInvestors expressed concerns regarding on-target KIT toxicities such as neutropenia, hair and skin color changes, as well as discontinuation rates.
---
Ownership Overview
27.43% Insiders
8.79% Mutual Funds
13.91% Other Institutional Investors
41.93% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JSPR FAQ
What was Jasper Therapeutics’s price range in the past 12 months?
Jasper Therapeutics lowest stock price was $4.00 and its highest was $31.01 in the past 12 months.
What is Jasper Therapeutics’s market cap?
Currently, no data Available
When is Jasper Therapeutics’s upcoming earnings report date?
Jasper Therapeutics’s upcoming earnings report date is Mar 11, 2025 which is in 121 days.
How were Jasper Therapeutics’s earnings last quarter?
Jasper Therapeutics released its earnings results on Nov 07, 2024. The company reported -$1.24 earnings per share for the quarter, missing the consensus estimate of -$1.071 by -$0.169.
Is Jasper Therapeutics overvalued?
According to Wall Street analysts Jasper Therapeutics’s price is currently Undervalued.
Does Jasper Therapeutics pay dividends?
Jasper Therapeutics does not currently pay dividends.
What is Jasper Therapeutics’s EPS estimate?
Jasper Therapeutics’s EPS estimate is -$1.25.
How many shares outstanding does Jasper Therapeutics have?
Jasper Therapeutics has 15,105,300 shares outstanding.
What happened to Jasper Therapeutics’s price movement after its last earnings report?
Jasper Therapeutics reported an EPS of -$1.24 in its last earnings report, missing expectations of -$1.071. Following the earnings report the stock price went down -4.262%.
Which hedge fund is a major shareholder of Jasper Therapeutics?
Among the largest hedge funds holding Jasper Therapeutics’s share is Woodline Partners LP. It holds Jasper Therapeutics’s shares valued at 9M.
---
Jasper Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$71.00 (189.44% Upside)
$71.00 (189.44% Upside)
Blogger Sentiment
Bullish
JSPR Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 34.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 7.7%
Last 30 Days ▲ 7.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
205.93%
12-Months-Change
Fundamentals
Return on Equity
-71.46%
Trailing 12-Months
Asset Growth
-9.96%
Trailing 12-Months
Company Description
Jasper Therapeutics
Amplitude Healthcare Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
---
JSPR Stock 12 Month Forecast
Average Price Target
$71.00
▲(189.44% Upside)
Technical Analysis
Sorrento Therapeutics
―
Adaptimmune Therapeutics
―
Eloxx Pharmaceuticals
―
Cellectis SA
―
Best Analysts Covering JSPR
1 Year
1 Year Success Rate
7/10 ratings generated profit
1 Year Average Return
+23.95%
reiterated a buy rating 2 days ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +23.95% per trade.
---